Currently Enrolling
1404-0115
Location(s): Jacksonville (LaVilla) & Fleming Island
For patients with Type 2 diabetes who control their blood sugar with diet/exercise, metformin, SGLT2i (such as Brenzavvy, Invokana, Farxiga, Jardiance or Steglatro), and/or insulin may qualify. The use of any other medications for diabetes is prohibited.
Learn moreAMAZE 2
Location(s): Fleming Island
A research study looking at the medication NNC0487-0111 and how it helps people with excess weight and Type 2 diabetes lose weight. Participants must have a desire and be committed to lose at least 25% of their body weight. Those with a history of bariatric surgery are excluded. Patients cannot be taking insulin or GLP-1 medications (such as Bydureon, Mounjaro, Ozempic, Trulicity, Victoza, Wegovy, or Zepbound) for at least one year.
Learn moreCagriMono
Location(s): Fleming Island
The purpose of this study is to understand how well cagrilintide is tolerated in patients who have previously discontinued a GLP-1 (such as Bydureon, Mounjaro, Ozempic, Trulicity, Victoza, Wegovy, or Zepbound) due to intolerable side effects. Individuals currently taking medications for diabetes, pre‑diabetes, or weight loss are excluded.
Learn moreENLIGHTEN-6
Location(s): Fleming Island
This study is exploring eloralintide in adults with persistent obesity who are currently taking a GLP-1 medication like Mounjaro, Ozempic, Wegovy, or Zepbound. Patients with or without Type 2 Diabetes will be included. Body weight must be stable, meaning no more than a 5% change in weight for at least four months. Those with a history of bariatric surgery are excluded. Diabetic patients cannot currently be taking insulin.
Learn moreEASi-PROTKT
Location(s): Jacksonville (LaVilla) & Fleming Island
A study for those with Type 2 Diabetes, high blood pressure, and cardiovascular disease. This includes patients who have had any of the following: Heart attack Stroke or mini stroke (TIA) Heart surgery (stent or bypass) Carotid artery surgery (to restore proper blood flow to the brain) Lower leg revascularization or amputation Imaging of the arteries that shows a blockage
Learn moreFORWARD
Location(s): Jacksonville (LaVilla) & Fleming Island
This study is assessing IMVT-1402 in adult participants with Graves’ Disease who have an over-active thyroid (hyperthyroidism) despite treatment with methimazole, carbimazole, or propylthiouracil. Patients who have undergone complete removal of the thyroid (total thyroidectomy) or who are currently taking thyroid supplementation (Synthroid, levothyroxine, NP Thyroid, or Armour Thyroid) are excluded.
Learn moreNN9838-7910
Location(s): Jacksonville (LaVilla) & Fleming Island
This study is enrolling adults with obesity to evaluate how different doses of CagriSema and semaglutide help people lose weight. Patients with and without Type 2 Diabetes may be included. Participants must have a desire and be committed to lose at least 25% of their body weight. Those with a history of bariatric surgery are excluded. Patients cannot be taking a GLP-1 medication (such as Bydureon, Mounjaro, Ozempic, Trulicity, Victoza, Wegovy, or Zepbound) for at least 6 months. Patients with diabetes cannot be taking insulin.
Learn moreONWARDS 11
Location(s): Jacksonville (LaVilla) & Fleming Island
This study is enrolling adults with Type 1 Diabetes who are not using an insulin pump. Participants must be willing to wear a CGM device and test their blood sugar daily.
Learn moreSOLARIS-1
Location(s): Jacksonville (LaVilla)
This study is investigating solbinsiran in adults with high triglyceride levels (≥ 500 mg/dL) who do not have a confirmed diagnosis of Familial Chylomicronemia Syndrome (confirmed by genetic testing). Patients who are on medication to treat cholesterol must be on a stable dose. Participants must agree to not start a structured weight loss program and be willing to limit alcohol consumption during the study.
Learn moreVitaliThy
Location(s): Fleming Island
A research study evaluating efgartigimod PH20 in adults with Graves’ Disease who have an over-active thyroid (hyperthyroidism) despite treatment with methimazole or carbimazole. Patients with a history of radioactive iodine therapy or who had removal of the thyroid (total thyroidectomy) will be excluded. Patients cannot be currently taking any medications that can affect thyroid hormone levels (including, Armour Thyroid, cholestyramine, levothyroxine, lithium, NP Thyroid, Synthroid, potassium iodide, or propylthiouracil).
Learn moreEnrollment Closed
ATTAIN-HYPERTENSION
For patients with high blood pressure that is either untreated or not well controlled on stable blood pressure medications. Those on dialysis or with certain types are heart failure are excluded. Patients cannot be taking insulin or GLP-1 medications (such as Bydureon, Mounjaro, Ozempic, Trulicity, Victoza, Wegovy, or Zepbound).
AVANTI
This study is examining the efficacy and safety of Armour Thyroid compared to Synthroid for the treatment hypothyroidism. Adults age 18 to 75 years who are taking synthetic T4 (Synthroid, Levoxyl, Levothroid, or levothyroxine) may qualify. Patients who have undergone total thyroidectomy as treatment for thyroid cancer may be eligible.
BaxDuo-ARCTIC
Adults with kidney disease and high blood pressure may qualify for this study comparing baxdrostat in combination with dapagliflozin (Farxiga) versus dapagliflozin (Farxiga) alone. The study is assessing the efficacy, safety and tolerability of baxdrostat on the progression of kidney disease. Participants must be on a stable dose of an ACEi (for example benazepril, enalapril, or lisinopril) or ARB (for example losartan or valsartan) for at least one month prior to screening. Patients taking medications such as spironolactone, finerenone, triamterene, or similar may be excluded.
NN9541-7841
For patients with chronic kidney disease (or protein in the urine) who are overweight or obese. Patients cannot be Patients cannot be taking GLP-1 medications (such as Bydureon, Mounjaro, Ozempic, Trulicity, Victoza, Wegovy, or Zepbound).
REDEFINE 11
A weight loss study enrolling non-diabetic patients who are comfortable losing 25% of their current body weight. Patients will be excluded if they are using weight loss medications (including GLP-1 like medications) or had a prior surgical treatment for obesity.
